COMP <GO>
BTMD vs ABBV // EV/EBITDA & P/E VALUATION
Biote Corp. (Class A) (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: BTMD 4
— ABBV 6
▲ EV/EBITDA & P/E VALUATION LEADER: BTMD
LAST: $1.17 (+1.74%) • MKT CAP: $42.0M
valuation
2.9x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BTMD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BTMD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 29.00% | +56.00 | BTMD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 2.9x | 33.3x | -30.40 | BTMD | /valuation <GO> |
| Free Cash Flow Yield | — | 3.47% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 18.50% | 24.60% | -6.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 14.10% | 6.90% | +7.20 | BTMD | /net-margins <GO> |
| Revenue Growth (YoY) | -2.50% | 8.60% | -11.10 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 4.11% | 2.27% | +1.84 | BTMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.50 | 5.33 | -2.83 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.5 | 65.1 | -21.56 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.0M | $513.86B | -$513.82B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BTMD REV | ABBV REV | BTMD GROSS % | ABBV GROSS % | BTMD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $192.2M | $61.16B | — | 70.2% | $30.2M | $17.82B |
| FY 2024 | $197.2M | $56.33B | — | 70.0% | $38.8M | $17.83B |
| FY 2023 | $185.4M | $54.32B | — | — | $26.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BTMD // BETA —
ABBV // BETA 1.15